Portfolio Lab

Mannkind Corp

  • Stock
  • Ticker MNKD
  • ISIN US56400P7069
  • Nasdaq

Health care · Pharmaceuticals · USA

$3.85 −2.53%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Mannkind Corp since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

MNKDGlobal equities (VT)

$10,000 grew to $12,621. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −87.5% in 03/2020, measured from the peak in 10/2017. It took 84 months to get back to the old peak.

1-year return
−22.5%
5-year return p.a.
−4.1%
10-year return p.a.
+2.4%
Volatility p.a.
75.5%
Largest decline
−87.5%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue7778778211290109102
Gross profit7275727898839591
Operating income26225.319-7.7-1.7-0.4-2.2
EBITDA29247.321-1.74.71.7-0.1
Net income7.4130.78.0-16-17-19-23
Earnings per share0.030.040.000.03-0.05-0.05-0.06-0.07
Balance sheet
Total assets394410412495792744732723
Liabilities473469467539843804800760
Equity-79-59-55-45-51-59-67-37
Cash46475712775535341
Long-term debt363636110355319319319
Cash flow
Operating cash flow23-6.49.024-8.0-5.4-18-35
Capital expenditure-2.9-0.3-1.1-1.1-2.0-1.9-5.1-3.2
Free cash flow20-6.77.823-10.0-7.2-23-38

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2020 at +142.6%, weakest 2018 at −54.3%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
5 Nov 2026−$0.07
5 Aug 2026−$0.06
6 May 2026−$0.05
26 Feb 2026−$0.05
5 Nov 2025$0.03
6 Aug 2025$0.00
8 May 2025$0.04
26 Feb 2025$0.03
7 Nov 2024$0.04
7 Aug 2024−$0.01
8 May 2024$0.04
27 Feb 2024$0.01

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.1bn
Market cap in trading currency
$1.24bn
Enterprise value
$1.46bn
P/E
–
P/S
3.00
P/B
–
EV/Sales
3.53
EV/EBITDA
315.8
Earnings yield
–
FCF yield
-6.3%

Results (last four quarters)

Revenue
$413m
Gross profit
$366m
EBITDA
$4.63m
Net income
−$74.8m
Earnings per share
−$0.23
Revenue per share
$1.29
Revenue growth
+24.0%
Earnings growth
−390.8%

Profitability

Gross margin
88.6%
Operating margin
-2.9%
Net margin
-18.1%
Return on equity
–
Return on assets
-10.4%

Balance sheet and cash flow

Cash
$96.6m
Cash per share
$0.30
Financial debt
$319m
Debt/equity %
–
Current ratio
2.22
Book value per share
−$0.12
Operating cash flow
−$66.2m
Free cash flow
−$78.4m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
322m
Volume
4.18m
Avg. volume 3 months
4.02m
Relative volume
1.1

Price and technicals

Price
$3.85
1 day
−2.5%
52-week high
$6.21
52-week low
$2.28
Distance to 52-week high
−38.0%
Distance to 52-week low
+68.9%
Distance to 50-day line
+7.7%
Distance to 200-day line
+6.9%
RSI (14)
52
Volatility 1M
48.9%

Performance

1 week
−6.8%
1 month
+20.3%
3 months
−5.4%
6 months
+13.9%
YTD
−32.1%
1 year
−23.0%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has MNKD performed since 11/2016?

$10,000 grew to $12,621 by 20 Nov 2026, which is +2.4% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is MNKD?

Volatility was 75.5% per year, measured on monthly returns. The largest decline from a peak was −87.5%, with the low in 03/2020.

How does MNKD compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, MNKD returned +2.4% at 75.5%. The correlation of monthly returns was 0.29; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Mannkind Corp (MNKD): Return and risk | Portfolio Lab